Epigenetic mechanisms in pulmonary arterial hypertension: The need for global perspectives

European Respiratory Review

Volumn 25, Issue 140, 2016, Pages 135-140

  Chelladurai, Prakash ^a   Seeger, Werner ^a,b   Pullamsetti, Soni Savai ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN CONTAINING PROTEIN 4; DNA; ENTINOSTAT; GRANULYSIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H1; MANGANESE SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; MICRORNA; MOCETINOSTAT; SEMAXANIB; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ANTIHYPERTENSIVE AGENT;

AIRWAY REMODELING; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; DISEASE SEVERITY; DNA METHYLATION; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; GENE LOCUS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE FAILURE; HIGH THROUGHPUT SEQUENCING; HISTONE ACETYLATION; HISTONE CODE; HISTONE MODIFICATION; HUMAN; LUNG ARTERY PRESSURE; MALIGNANT NEOPLASTIC DISEASE; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; ANIMAL; ARTERIAL PRESSURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; GENOMICS; HYPERTENSION, PULMONARY; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; PULMONARY ARTERY; RISK FACTOR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; MOLECULAR TARGETED THERAPY; PHENOTYPE; PULMONARY ARTERY; RISK FACTORS;

EID: 84971520414     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0036-2016     Document Type: Article

References (41)

1. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:, D42-D50.
2. Montani D, Günther S, Dorfmüller P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis 2013; 8: 97.
3. Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: Suppl., D13-D21.
4. Austin ED, Loyd JE. Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 2013; 34: 568-580.
5. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007; 128: 635-638.
6. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 2008; 10: 25-36.
7. Trerotola M, Relli V, Simeone P, et al. Epigenetic inheritance and the missing heritability. Hum Genomics 2015; 9: 17.
8. Bönisch C, Hake SB. Histone H2A variants in nucleosomes and chromatin: more or less stable? Nucleic Acids Res 2012; 40: 10719-10741.
9. Li M, Riddle SR, Frid MG, et al. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol 2011; 187: 2711-2722.
10. Masri FA, Xu W, Comhair SA, et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 293: L548-L554.
11. Meloche J, Potus F, Vaillancourt M, et al. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res 2015; 117: 525-535.
12. Zhou G, Chen T, Raj JU. MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2015; 52: 139-151.
13. Kim JD, Lee A, Choi J, et al. Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. Exp Mol Med 2015; 47: e175.
14. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1: 239-259.
15. Gao F, Liang H, Lu H, et al. Global analysis of DNA methylation in hepatocellular carcinoma by a liquid hybridization capture-based bisulfite sequencing approach. Clin Epigenetics 2015; 7: 86.
16. Kim GH, Ryan JJ, Marsboom G, et al. Epigenetic mechanisms of pulmonary hypertension. Pulm Circ 2011; 1: 347-356.
17. Archer SL, Marsboom G, Kim GH, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010; 121: 2661-2671.
18. Perros F, Cohen-Kaminsky S, Gambaryan N, et al. Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2013; 187: 189-196.
19. Cohen I, Poręba E, Kamieniarz K, et al. Histone modifiers in cancer: friends or foes? Genes Cancer 2011; 2: 631-647.
20. Zhao L, Chen CN, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012; 126: 455-467.
21. Kim J, Hwangbo C, Hu X, et al. Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation 2015; 131: 190-199.
22. Cavasin MA, Demos-Davies K, Horn TR, et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 2012; 110: 739-748.
23. Lemon DD, Harrison BC, Horn TR, et al. Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle. FEBS Lett 2015; 589: 1080-1088.
24. Nebbioso A, Manzo F, Miceli M, et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 2009; 10: 776-782.
25. Cavasin MA, Stenmark KR, McKinsey TA. Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series). Pulm Circ 2015; 5: 63-72.
26. Cho YK, Eom GH, Kee HJ, et al. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J 2010; 74: 760-770.
27. Kong Y, Tannous P, Lu G, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006; 113: 2579-2588.
28. Bogaard HJ, Mizuno S, Hussaini AA, et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011; 183: 1402-1410.
29. De Raaf MA, Hussaini AA, Gomez-Arroyo J, et al. Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series). Pulm Circ 2014; 4: 237-243.
30. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014; 13: 337-356.
31. Talati M, Seeley E, Ihida-Stansbury K, et al. Altered expression of nuclear and cytoplasmic histone H1 in pulmonary artery and pulmonary artery smooth muscle cells in patients with IPAH. Pulm Circ 2012; 2: 340-351.
32. Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
33. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41: 178-186.
34. Sharma P, Garg G, Kumar A, et al. Genome wide DNA methylation profiling for epigenetic alteration in coronary artery disease patients. Gene 2014; 541: 31-40.
35. Simmer F, Brinkman AB, Assenov Y, et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 2012; 7: 1355-1367.
36. Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One 2012; 7: e33770.
37. Bertero T, Lu Y, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 2014; 124: 3514-3528.
38. Rajkumar R, Konishi K, Richards TJ, et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010; 298: H1235-H1248.
39. Bull TM, Coldren CD, Moore M, et al. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 911-919.
40. Rhodes CJ, Im H, Cao A, et al. RNA sequencing analysis detection of a novel pathway of endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 356-366.
41. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67-119.